Moderna Beats Q3 Sales Expectations But Posts Wider Losses, Issues Cautious Outlook

Moderna beat Q3 sales expectations but reported bigger losses than expected and issued light guidance.

Moderna is gaining market share with its updated Covid booster but expects sales to dip to $4B in 2024 before rebounding.

The company aims to launch 15 new products by 2028, with the RSV vaccine coming in 2024.

Moderna has 6 drugs in late-stage testing, including cancer vaccines with Merck.

Analysts say Moderna needs pipeline successes starting in 2024-2025 to bounce back from expected sales decline.